Clinical Trials Logo

Skin Squamous Cell Cancer clinical trials

View clinical trials related to Skin Squamous Cell Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02268747 Active, not recruiting - Clinical trials for Skin Squamous Cell Cancer

Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer

Start date: November 2014
Phase: Phase 2
Study type: Interventional

This is an open label, monocentric, uncontrolled phase II trial with Dacomitinib, a pan-HER inhibitor, in unresectable or metastatic skin SCC. HER2 expression is common in skin SCC, being reported with high rates, even if in small studies. Coexpression of EGFR, HER2 and HER3 is present in skin SCCs but not in normal skin and it could be associated with the malignant phenotype. In this frame Dacomitinib could play a role in the increase of the response rate.